HR 1873
117th Congress
House
Health
Drug safety, medical device, and laboratory regulation
Government information and archives
Health personnel
Licensing and registrations
Medical education
Prescription drugs
Advancing Education on Biosimilars Act of 2021
Introduced: March 12, 2021
See on congress.gov
Everywhere this bill has been
3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Mar 16, 2021
Referred to the Subcommittee on Health.
Mar 12, 2021
Referred to the House Committee on Energy and Commerce.
Mar 12, 2021
Introduced in House
Plain-English summary
Advancing Education on Biosimilars Act of 2021
This bill requires the Food and Drug Administration (FDA) to advance education and awareness among health care providers about biological products as appropriate, including by developing or improving continuing education programs that address the prescribing of biological products and biosimilars. (A biosimilar is a biological product that is highly similar to an FDA-approved reference biological product and has no clinically meaningful differences from that reference product.)
The FDA may also maintain and operate a website to provide educational materials about biological products.
What's happening now
Referred to the Subcommittee on Health.
Committees of jurisdiction
2
Cosponsors
1